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Parkinson’s disease (PD) is a neurodegenerative disease in which
genetic risk has been mapped to HLA, but precise allelic associa-
tions have been difficult to infer due to limitations in genotyping
methodology. Mapping PD risk at highest possible resolution, we
performed sequencing of 11 HLA genes in 1,597 PD cases and 1,606
controls. We found that susceptibility to PD can be explained by a
specific combination of amino acids at positions 70–74 on the HLA-
DRB1 molecule. Previously identified as the primary risk factor in
rheumatoid arthritis and referred to as the “shared epitope” (SE),
the residues Q/R-K/R-R-A-A at positions 70–74 in combination with
valine at position 11 (11-V) is highly protective in PD, while risk is
attributable to the identical epitope in the absence of 11-V. Nota-
bly, these effects are modified by history of cigarette smoking,
with a strong protective effect mediated by a positive history of
smoking in combination with the SE and 11-V (P = 10−4; odds ratio,
0.51; 95% confidence interval, 0.36–0.72) and risk attributable to
never smoking in combination with the SE without 11-V (P = 0.01;
odds ratio, 1.51; 95% confidence interval, 1.08–2.12). The associa-
tion of specific combinations of amino acids that participate in
critical peptide-binding pockets of the HLA class II molecule impli-
cates antigen presentation in PD pathogenesis and provides fur-
ther support for genetic control of neuroinflammation in disease.
The interaction of HLA-DRB1 with smoking history in disease pre-
disposition, along with predicted patterns of peptide binding to
HLA, provide a molecular model that explains the unique epide-
miology of smoking in PD.
Parkinson’s disease | HLA | smoking | shared epitope
Parkinson’s disease (PD; MIM: 168600) is a chronic, progressiveneurodegenerative disease characterized by bradykinesia, tremor,
rigidity, and postural instability plus a constellation of associated
features including autonomic, sensory, cognitive, and psychologi-
cal changes. With both familial and sporadic forms of the disease
and a clear genetic component, numerous genome-wide associa-
tion studies (GWAS), fine-mapping, and candidate gene studies
over the past two decades have revealed dozens of risk-associated
genetic variants. Consistent with underlying immunoregulatory
dysfunction and inflammatory processes operating in PD, immune
system genetic factors are consistently represented among repli-
cated PD loci. Most notably, a clear association peak has been
shown to map to the major histocompatibility complex (MHC) on
chromosome 6 (6p21.3), which houses the HLA genes.
HLA class II gene products are expressed on the surface of
professional antigen-presenting cells, which generally present
peptide fragments of extracellular origin to helper (CD4+)
T cells (1). HLA class I molecules are expressed on all nucleated
cells and present antigens originated from intracellular sources to
cytotoxic (CD8+) T cells for killing tumorous or infected cells (2).
While an association of HLA class I with PD was first observed
more than four decades ago (3), more contemporaneous single
nucleotide polymorphism (SNP) associations point to the class II
region of the locus (4, 5). In an early GWAS, the association peak
in the MHC was found with rs3129882 within HLA-DRA (MIM:
142860) (6), although attempts to replicate this observation have
generated varied and conflicting results (7–13).
Recent large studies have used SNP-based GWAS to fine-map
the MHC association signal and to impute functional alleles of
the HLA system (4, 5, 12, 14–17), but the complexity of the re-
gion presents major challenges for studies aimed at defining the
causative variants. Extremely high levels of polymorphism,
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structural variation, an extensive history of gene duplication,
conversion and recombination events, and unusually high levels
of linkage disequilibrium (LD) confound attempts to infer pre-
cise allelic associations from SNP data (18). The few studies that
have directly queried HLA variation through traditional geno-
typing methods have produced mixed results and have been
hampered by a relatively small sample size, low-resolution HLA
genotyping methodology, or both (19–22).
To unravel the immunogenetic underpinnings of the disease,
we undertook a large-scale deep-sequencing study of the HLA
genes in PD. We analyzed HLA variation at high resolution using
a well-validated next-generation sequencing (NGS) method in 1,941
PD cases and 1,612 controls from the United States with European
ancestry. By sequencing comprehensively across 11 full-length HLA
genes— HLA-DRB1 (MIM: 142857), HLA-DRB3 (MIM: 612735),
HLA-DRB4, HLA-DRB5 (MIM: 604776), HLA-DQA1 (MIM:
146880), HLA-DQB1 (MIM: 604305), HLA-DPA1 (MIM: 142880),
HLA-DPB1 (MIM: 142858), HLA-A (MIM:142800), HLA-B
(MIM: 142830), and HLA-C (MIM: 142840)—we were able to
examine associations at the highest possible resolution, yielding the
most complete representation to date of the complex immunoge-
netics underlying PD. We found that protection in PD can be
explained by a specific epitope at positions 70–74 on the HLA-
DRB1 molecule in combination with valine at position 11 (11-V),
while risk is attributable to the identical epitope in the absence of
11-V, and that these effects are modified by a history of cigarette
smoking. In identifying the source of association signals in the
disease and interaction with a key environmental factor, we pro-
vide a framework for understanding the nature of the immune
component in PD pathogenesis.
Results
High-Resolution Genotyping Demonstrates That Risk and Protection
in PD Are Mediated by HLA-DRB1. All 11 of the highly-polymorphic
HLA class I and II genes were sequenced from 1,597 PD cases
and 1,606 controls (SI Appendix, Table S1). We first analyzed
data for the entire molecule at polypeptide sequence resolution,
described in the HLA nomenclature by the first two fields of the
allele name (23), to examine the entire functional unit of interest. In
this analysis, we considered results sufficient to warrant follow-up
when significant at a false discovery rate (FDR) (24) of 10%, cor-
responding to a cutoff of P= 0.02.We found strong protective effects
for HLA-DRB1*04:01 [P = 0.007; odds ratio (OR), 0.78; 95% con-
fidence interval (CI), 0.65–0.93] and HLA-DQB1*03:02 (P = 0.006;
OR, 0.78; 95%CI, 0.66–0.93) (Fig. 1). These alleles are in strong LD,
forming part of the HLA-DQA1*03:01∼HLA-DQB1*03:02∼HLA-
DRB1*04:01 class II haplotype, which is also significantly associated
with disease (P = 0.008; OR, 0.66; 95% CI, 0.54–0.84). Confirming
HLA-DRB1 as the source of this signal, another HLA-DRB1*04:01–
containing haplotype,HLA-DQA1*03:03∼HLA-DQB1*03:01∼HLA-
DRB1*04:01, was observed at nearly equal frequency (Table 1) and is
also significantly protective against developing PD (P = 0.005; OR,
0.66; 95% CI, 0.54–0.85). While both haplotypes are in LD with
HLA-DRB4*01:03, this allele may be excluded as causative because
it is also observed in some HLA-DRB1*07:01 haplotypes not asso-
ciated with disease. Furthermore, no association remained for HLA-
DQB1*03:02 on conditioning on HLA-DRB1*04:01.
Complementing this finding, we observed borderline signifi-
cance for PD risk mediated by HLA-DRB1*01:01 (P = 0.012;
OR, 1.26; 95% CI, 1.05–1.50). This result remained significant
after conditioning for HLA-DRB1*04:01 (P = 0.02; OR, 1.23;
Fig. 1. Association analysis results for all HLA class I and class II alleles. HLA alleles that were detected in the study population are shown around the pe-
rimeter. Decreasing P values are indicated by the distance of points from the center, with P = 0.01 indicated by the black dotted concentric line. The
magnitude of ORs is indicated by the diameter of points, with filled points indicating OR >1 and open points indicating OR <1. The magnitude of global
linkage disequilibrium between loci is indicated by the width of interior lines.
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95% CI, 1.03–1.49), confirming it as an independent association.
HLA-DRB1*01:01 is observed in near-complete LD with HLA-
DQA1*01:01 and HLA-DQB1*05:01 as a haplotype in pop-
ulations with European ancestry (25, 26). Although we also
found similar associations and significance levels for the HLA-
DQA1 and HLA-DQB1 alleles of this haplotype (Fig. 1), their
effect sizes were smaller, and on conditioning for HLA-
DRB1*01:01, no effect remained for these alleles. This finding
suggests that any observed HLA-DQA1/-DQB1 association is
attributable to LD with the primary predisposing allele, HLA-
DRB1*01:01. Taken together, our results strongly implicate
HLA-DRB1 as the operative locus in disease.
Our genotyping methodology provides information for virtu-
ally all coding and noncoding variations at the HLA loci; how-
ever, we did not observe any appreciable differences between
cases and controls with respect to noncoding variation at any
locus. Likewise, there were no significant differences between
cases and controls for alleles of any class I locus (HLA-A, -B,
and -C) or class II loci HLA-DPA1, HLA-DPB1, HLA-DRB3,
HLA-DRB4, and HLA-DRB5 after conditioning on the HLA-
DRB1 associations. Similarly, tests for interaction between HLA
alleles and between HLA and known PD risk SNPs, when avail-
able in our dataset, did not yield any significant results.
Specific Amino Acid Residues of HLA-DRB1 Mediate Risk and
Protection in PD. To decipher the precise structural elements
mediating the suggested HLA-DRB1 associations with PD, we
examined the contribution of individual amino acids of the HLA-
DRB1 molecule to disease risk. Omnibus testing revealed four
positions to be significantly associated with PD: 11 (P = 0.002;
pcorr = 0.05), 13 (P = 0.001; pcorr = 0.04), 26 (P = 0.001; pcorr =
0.03), and 33 (P = 0.001; pcorr = 0.04). Of these, positions 11, 13,
and 26 are highly polymorphic and occupy key positions in the
peptide-binding groove of the class II molecule. Results of
analysis of amino acid variation for each position are provided in
SI Appendix, Table S2. The effect at position 26 is driven by
phenylalanine, mediating protection (P = 3 × 10−5; OR, 0.79;
95% CI, 0.71–0.89). Position 11 is extremely polymorphic, with
six different residues observed across this dataset; of these, sig-
nificant associations are observed for valine, which mediates
protection (P = 0.006; OR, 0.83; 95% CI, 0.73–0.95), and lysine,
which mediates risk (P = 0.006; OR, 1.24; 95% CI, 1.06–1.44).
Position 13 is also extremely polymorphic and is in very strong
yet incomplete LD with position 11; however, the association at
this position appears to be driven mainly by a protective effect of
histidine (P = 0.005; OR, 0.82; 95% CI, 0.72–0.95). Examination
of these amino acid associations in a replication cohort of an
additional 462 controls and 536 PD patients confirms the find-
ings for 11-V (P = 0.02; OR, 0.7; 95% CI, 0.51–0.97) and 13-H
(P = 0.03; OR, 0.7; 95% CI, 0.5–0.97).
The protective effects observed for 11-V, 13-H, and 26-F can
be attributed to association of these variants with alleles of the
HLA-DRB1*04 lineage, aligning with our initial observation of
protection mediated by HLA-DRB1*04:01. Likewise, 11-L is
specific to alleles of the HLA-DRB1*01 lineage, in line with our
observation of risk mediated by HLA-DRB1*01:01. Thus, while
the extreme levels of polymorphism at HLA-DRB1 hampers our
power to confirm high-resolution allelic associations beyond
10% FDR or to fully account for the burden of multiple com-
parisons, the totality and context of variation at individual amino
acids support our initial observations in high-resolution alleles.
Indeed, combining alleles of the HLA-DRB1*04 lineage, we find
significant protection at this resolution (P = 0.001, pcorr = 0.01;
OR, 0.79; 95% CI, 0.69–0.91). Confirming this observation,
HLA-DRB1*04 is also significantly protective in our replication
cohort, with a nearly identical effect size (P = 0.04; OR, 0.77;
95% CI, 0.60–0.99).
The “Shared Epitope” and Position 11 Explain HLA Associations in PD.
Notably, along with HLA-DRB1*01:01, which we find to be
predisposing in PD, HLA-DRB1*04:01 and HLA-DRB1*10:01
share a common set of amino acids at positions 70–74 (70-Q/R,
71-R/K, 72-R, 73-A, and 74-A), referred to as the “shared epi-
tope” (SE) and originally described with respect to pre-
disposition to rheumatoid arthritis (RA; MIM: 180300) (27). In
our dataset, seven HLA-DRB1 alleles have the SE, including
HLA-DRB1*10:01 and additional alleles of the HLA-DRB1*04
and HLA-DRB1*01 lineages (Table 2). Looking more closely at
the lower-frequency HLA-DRB1*04 alleles in our dataset, we
observed that only HLA-DRB1*04 alleles with the SE are in-
creased in controls compared with PD cases (Table 2), while
those without the SE are not.
Given these findings, we examined the association of HLA-
DRB1 with PD with respect to the SE in combination with po-
sition 11-V. We found that the risk for PD is mediated by the SE
in the absence of 11-V (P = 0.01; OR, 1.25; 95% CI, 1.05–1.50).
While not statistically significant, a trend toward a risk for the SE
without 11-V was seen in our replication cohort. Most striking,
we found that protection in PD can be explained by the SE in
combination with 11-V (P = 0.001; OR, 0.76; 95% CI, 0.64–
0.89), and that this result is clearly reproducible in our replica-
tion cohort (P = 0.01; OR, 0.61; 95% CI, 0.42–0.90), confirming
a role for this specific set of amino acids in disease.
Smoking History and the HLA SE Interact in Risk and Protection in PD.
A protective effect of cigarette smoking in PD is well established
(28). Moreover, recent work suggests an interaction between
smoking history and variation in HLA-DRB1 in disease (17), but
that analysis examined only a single SNP in the locus. Having
identified the SE as the structural variant of HLA-DRB1 asso-
ciated with disease, we sought to examine in greater detail the
role of smoking history in combination with HLA variation. We
analyzed the interaction of smoking history with the HLA-DRB1
SE in 837 PD cases and 918 controls for whom data on cigarette
smoking history were available. These individuals had self-reported
as either a former or current smoker or having never smoked; for
Table 1. HLA-DQA1∼DQB1∼DRB1 haplotype frequencies in PD
cases and controls
DQA1∼DQB1∼DRB1 Control frequency Case frequency
01:02∼06:02∼15:01 0.124 0.122
05:01∼02:01∼03:01 0.114 0.137
02:01∼02:02∼07:01 0.091 0.092
01:01∼05:01∼01:01 0.079 0.099
01:03∼06:03∼13:01 0.055 0.053
05:05∼03:01∼11:01 0.051 0.051
03:03∼03:01∼04:01 0.047 0.039
03:01∼03:02∼04:01 0.037 0.031
05:05∼03:01∼11:04 0.037 0.031
01:02∼06:04∼13:02 0.034 0.034
02:01∼03:03∼07:01 0.033 0.038
03:01∼03:02∼04:04 0.032 0.027
01:04∼05:03∼14:54 0.02 0.02
01:02∼05:02∼16:01 0.019 0.011
04:01∼04:02∼08:01 0.018 0.02
05:05∼03:01∼12:01 0.017 0.02
03:01∼03:02∼04:02 0.015 0.012
01:01∼05:01∼01:02 0.014 0.016
01:02∼06:09∼13:02 0.013 0.01
01:03∼06:01∼15:02 0.011 0.008
01:01∼05:01∼01:03 0.011 0.011
05:05∼03:01∼13:03 0.01 0.01
03:03∼03:01∼04:07 0.009 0.01
Hollenbach et al. PNAS | April 9, 2019 | vol. 116 | no. 15 | 7421
G
EN
ET
IC
S
our analysis, we dichotomized these groups into those with any
history of smoking and those with no history of smoking. HLA-
DRB1 alleles were coded according to the presence of the SE with
and without 11-V (SE+V11+ and SE+V11−), and the impact on
disease occurrence was determined by multiple logistic regression
with gender, principal component (PC) 1, PC2, PC3, and PC4 as
covariates. No significant differences with respect to SE frequen-
cies were observed between individuals for whom smoking data
were available and those for whom it was not available (SI Ap-
pendix, Table S3).
To study whether the effect of the SE genotype on disease was
modified by smoking history, an interaction term (SE × smoking
history) was included in the model. The importance of each
possible risk factor under consideration was assessed by the
Wald test and confirmed by the likelihood ratio test on the de-
viance of the model. We found that the interaction between
positive smoking history and homozygosity for SE+V11+ alleles
was significant (P = 0.02), suggesting that protection mediated by
SE+V11+ HLA-DRB1 alleles was further enhanced by a history
of smoking. The data show that the combined effect of a history
of smoking with the presence of one or two SE+V11+ alleles was
highly protective in PD (P = 10−4; OR, 0.51; 95% CI, 0.36–0.72)
(SI Appendix, Table S4), with an effect size greater than that
when considering HLA-DRB1 alone in the same individuals
(OR, 0.65; 95% CI, 0.52–0.82). Likewise, the interaction term for
a negative history of smoking with homozygosity for SE+V11−
alleles also showed a strong trend (P = 0.06), and we found that a
history of having never smoked in combination with SE+V11−
alleles are predisposing to PD (P = 0.01; OR, 1.51; 95% CI,
1.08–2.12), with a greater effect size than for HLA alone (OR,
1.29; 95% CI, 1.01–1.66). Thus, it appears that the protective
effect in PD of a positive history of smoking can be explained in
part by interaction with HLA variation, suggesting that molecular
changes mediated by cigarette smoke may be involved in alter-
ation of HLA antigen presentation.
Citrullination of α-Synuclein Peptides Is Predicted to Alter Binding
Affinity to HLA SE Alleles. Because α-synuclein aggregates in the
PD brain, and T-cell recognition of α-synuclein peptides by PD
patients has been recently reported and proposed as an auto-
antigen in disease (29), we explored the binding affinity of
peptides derived from α-synuclein to the HLA SE allotypes using
a bioinformatic prediction method. We used the NetMHCII3.2
server (30) to predict binding of peptides from α-synuclein to SE
alleles associated with PD risk (V11−) or protection (V11+). We
input the entire protein sequence of α-synuclein and predicted
the probable peptides that bind to HLA-DRB1*01:01 and *01:02
(SE+V11−) and to HLA-DRB1*04:01, *04:04, and *04:05
(SE+V11+). Overall, we found that peptides derived from
α-synuclein were predicted to bind with higher affinity to SE+
V11− (risk) alleles compared with SE+V11+ (protective) alleles
(P = 0.004); in fact, among the 126 peptides tested, none reached
the threshold for predicted binding (<500 nM) to the SE+V11+
alleles (SI Appendix, Table S5).
Given our finding that a history of smoking in our cohort in-
teracts with HLA-DRB1 in PD, and that smoking significantly
increases posttranslational modifications such as citrullination
and homocitrullination (31), which in turn may alter peptide-
binding affinity for HLA class II (32), we performed replicate
peptide-binding predictions with all lysine modified to homoci-
trulline residues (SI Appendix, Table S6). For SE+V11− alleles,
peptide modification is predicted to reduce the binding affinity
of α-synuclein (P = 2.2 × 10−16). Conversely, peptide modifica-
tion is predicted to increase the overall binding affinity to the
SE+V11+ alleles (P = 0.0001). Importantly, the predicted in-
crease in affinity for the SE+V11+ alleles resulted in a number of
α-synuclein–derived peptides meeting the affinity threshold for
binding. These results suggest that posttranslational modification
of peptides mediated by cigarette smoking may simultaneously
increase peptide affinity for protective HLA-DRB1 alleles such
as HLA-DRB1*04:01 and decrease peptide affinity for risk HLA-
DRB1 alleles such as HLA-DRB1*01:01.
Discussion
Despite clear evidence for the role of HLA in genetic pre-
disposition to PD, the complex and highly polymorphic character
of the region has been a barrier to defining the precise nature of
its contribution to disease. Here we have performed deep se-
quencing across entire genes of all polymorphic classical HLA
loci. In doing so, we were able to identify the specific amino acids
and elucidate structural features mediating both risk and pro-
tection in PD. Our data establish that the entirety of HLA risk
and protection in PD can be explained by the SE of HLA-DRB1
at positions 70–74 in the β-chain α-helix defining the sides of the
peptide-binding groove, in combination with position 11 in the
β-pleated sheet on the floor of the groove.
While our findings are in agreement with numerous previous
studies that have identified HLA-DRB1*04 alleles as protective
in PD (12, 14, 17, 20), by examining the HLA genes at sequence
level resolution we refine these observations to clarify that only
alleles of this lineage bearing the SE are protective. Extending
the understanding of the role of HLA in PD, we find that an-
other SE allele, HLA-DRB1*01:01, is predisposing in disease.
While HLA-DRB1*01:01 has not been previously associated with
PD, a recent meta-analysis of genome-wide studies in PD iden-
tified HLA-DRB6, a pseudogene on the same haplotype, as a risk
allele in PD (33).
Originally defined in rheumatoid arthritis, the “SE hypothesis”
sought to explain the HLA-DRB1 predisposition to disease
across several allelic lineages (27). Among Europeans, the most
common SE alleles belong to the HLA-DRB1*01 and HLA-
DRB1*04 lineages and are predisposing to RA. The crystal
structures for the SE alleles HLA-DRB1*01:01 and HLA-
DRB1*04:01 reveal many mutual features with respect to the
antigen-binding groove and have been shown to present several
peptides in common; for example, both alleles have been crys-
tallized with influenza virus protein hemagglutinin residues 306–
318 (34). In contrast to RA, our observation in PD is of opposing
effects for these alleles, with the direction of effect mediated by
the presence or absence of 11-V; however, it is within reason that
both risk and protective alleles present the same peptide.
In support of that model, a landmark study examining HLA
function in Goodpasture disease demonstrated that risk vs. pro-
tective HLA alleles presenting the same immunodominant autor-
eactive peptide can produce markedly different T-cell responses
(35), with the protective allele producing a more regulatory phe-
notype. We propose that HLA peptide specificity in PD is de-
termined by the SE, residues of which participate in the P4, P7,
and P9 pockets of the peptide- binding groove (36), while the shift
Table 2. Amino acid residues for HLA-DRB1 allotype SE
and position 11 and frequencies in PD cases and controls
HLA-DRB1 11 70 71 72 73 74 Controls Cases
01:01 L Q R R A A 0.083 0.099
01:02 L Q R R A A 0.014 0.016
04:01 V Q K R A A 0.085 0.076
04:04 V Q R R A A 0.034 0.027
04:05 V Q R R A A 0.006 0.004
04:08 V Q R R A A 0.006 0.004
10:01 V R R R A A 0.009 0.008
The HLA-DRB1 SE is defined as residues Q/R-K/R-R-A-A at position 70–74.
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to a regulatory phenotype is mediated by 11-V, which defines the
specificity for the P6 pocket (Fig. 2).
Our observation that the protective effect of cigarette smoking
interacts with the HLA-DRB1 SE draws another intriguing par-
allel to RA. In contrast to the protection afforded in PD,
smoking is a well-established risk factor in RA (37). A common
feature in RA is the presence of antibodies to citrullinated
protein antigens (38), the generation of which has been associ-
ated with smoking (39). Further evidence suggests that citrulli-
nation enhances the binding affinity of some arithrogenic
peptides to SE alleles (40), suggesting a pathway for interaction
between smoking and HLA in RA. Our finding that citrullination
increases the predicted affinity for HLA-DRB1 alleles protective
in PD while decreasing the predicted affinity for HLA-DRB1
alleles predisposing to PD supports the notion that the epide-
miologic association of smoking in both RA and PD is mediated
by its posttranslational modification of antigens presented by
HLA-DRB1. Finally, and in support of these observations, epi-
demiologic studies have shown that individuals with RA are at
reduced risk of developing PD (41).
These results also lend credence to the notion that PD is, at
least in part, autoimmune in nature. Further underscoring this
notion, a recent study demonstrating T-cell autoreactivity to
HLA class II presented peptides derived from α-synuclein, which
accumulates in the PD brain (29), suggested that neuronal loss
may be mediated by autoimmune mechanisms.
In summary, we find a clear and replicable role for HLA class
II in predisposition and protection in PD and provide an ex-
planation for the association of smoking with protection from
disease. The association of specific combinations of amino acids
that participate in critical peptide-binding pockets of the HLA
class II molecule implies antigen presentation as a key factor in
disease and strongly supports a role for immunogenetic variation
in mediating the immunopathology of PD.
Methods
The study was approved by the University of California San Francisco (UCSF)
Institutional Review Board.
Datasets.
Discovery cohort. The discovery cohort consisted of the National Institutes of
Health (NIH)-GWAS and NIH-NeuroX datasets derived from the National In-
stitute of Neurological Disorders and Stroke-funded Neurogenetics Repository
at the Coriell Institute for Medical Research, as well as the UCSF- GeneMSA
dataset. After initial quality controls performed on HLA sequencing data, 3,647
samples with calling at all loci were received for analysis. Patients were removed
from the discovery dataset if (i) they did not have available SNP data, (ii) they
self-identified as nonwhite or non-Caucasian, (iii) they had an SNP genotyping
rate <90% (see below), or (iv) the genetic population stratification analysis
identified them as outliers (see below). The number of patients removed at
each step of sample quality control is presented in SI Appendix, Table S7. This
process resulted in a discovery dataset of 1,606 controls and 1,597 PD patients.
Replication cohort. The replication cohort consisted of two Michael J. Fox
Foundation for Parkinson’s Research datasets (BioFIND and DATATOP) and
UCSF controls (UCSF1). Patients were removed from the replication dataset if
(i) they did not have an allele call at all loci considered for replication (HLA-
DQA1, HLA-DQB1, and HLA-DRB1) or (ii) they self-identified as nonwhite or
non-Caucasian or of Hispanic origin (SI Appendix, Table S8). Because no SNP
data were available for these datasets, genetic population stratification was
not performed. This process resulted in a replication dataset of 462 controls
and 536 PD patients.
Demographic data for the discovery and replication cohorts are presented
in SI Appendix, Table S9. All patients were non-Hispanic whites from the
United States with idiopathic PD. All controls are reported to be unrelated
non-Hispanic white and free from neurologic disorders. Informed consent
was obtained for each participant under locally approved protocols.
SNP Data. Samples from the NIH dataset were genotyped on one of two
Illumina arrays, the Immunochip or the NeuroX chip, which we refer to as the
NIH-GWAS and NIH-NeuroX datasets, respectively. Some of the UCSF controls
were genotyped on the HumanHap 550 BeadChip and are referred to as
UCSF-GeneMSA dataset. For the UCSF-GeneMSA dataset, SNP positions were
updated to the HG19 assembly using the LiftOver tool (https://genome.ucsc.
edu/cgi-bin/hgLiftOver). Quality controls on samples included the genotyp-
ing rate per individuals and genetic outlier assessment, defined as individ-
uals >6 SDs outside the mean for the first 10 PCs. Quality controls on SNPs
included duplicated variant removal, Hardy–Weinberg equilibrium de-
parture (P < 0.001), and low SNP call rate (<95%) (SI Appendix, Table S10).
Quality control checks were performed at the dataset level, using R (42) and
Plink v1.07 (43) software.
Control for Population Stratification. Population stratification analysis was
performed using a core set of 8,006 SNPs. These 8,006 SNPs remained after
excluding those that (i) did not pass quality control checks as described
above; (ii) were not genotyped in the NIH-GWAS, NIH-NeuroX, and UCSF-
GeneMSA datasets; (iii) were located on nonautosomal chromosomes; (iv)
were from the extended MHC region (all markers on chromosome 6 from 26
to 36 Mb); (v) were from other regions of extended LD (all markers on
chromosome 8 from 6 to 16 Mb and on chromosome 17 from 40 to 45 Mb);
(vi) had a minor allele frequency <1%; or (vii) were from LD pruning so that
no marker had a pairwise r2 > 0.1 with any marker within a 100-SNP win-
dow. SNP data management was done using R (42) and Plink v1.07 (43). PCs
were computed using the SNPRelate R package (44) on the final set of SNPs.
Samples at >6 SDs from the mean for any of the first 10 PCs were considered
population-specific outliers and removed (SI Appendix, Fig. S1). Using a final
set of 7,918 SNPs, population stratification was also performed in regard to
the 1000 Genomes white samples (SI Appendix, Fig. S2). A total of 12 sam-
ples were removed using these criteria.
HLA Next-Generation Sequencing and Genotyping. DNA samples were typed
for 11HLA loci—HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1, -DRB1, -DRB3, -DRB4,
and -DRB5—using the MIA FORA NGS high-throughput typing kit and analysis
software (Immucor) and performed according to the manufacturer’s semi-
automated protocol. Details are provided in SI Appendix, Methods.
Statistical Analysis. All analyses were performed in R (42). Associations of HLA
alleles with disease were tested at all levels of resolution using logistic re-
gression. Conditioned analyses were performed by adding specific alleles/
variants of interest as covariates. Only HLA alleles with a frequency >1%
were analyzed. Frequencies of HLA alleles and an omnibus test for associa-
tion with specific amino acids were computed using the BIGDAWG R pack-
age (45). Logistic regression was also used to test for interactions between
HLA alleles and between HLA alleles and known PD risk SNPs. Haplotype
estimations and association analyses with disease were performed using
the “haplo.glm” function in the haplo.stats R package (46), with gender and
the first four PCs as covariates. All analyses were adjusted for gender and the
first four PCs to correct for population stratification (SI Appendix, Fig. S3).
Fig. 2. HLA-DRB1 amino acid positions mediating risk and protection in PD.
Position 11 (pink) is located in the β-pleated sheet on the floor of the peptide-
binding groove of the HLA-DR molecule. The SE at positions 70–74 (green) is lo-
cated on the second α-helix, bordering the peptide-binding groove of HLA-DR.
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To test for interaction between smoking history and HLA, the model
parameters of logistic regression were estimated using the maximum like-
lihood method. The Wald test was used to test the mean difference between
the estimated coefficient and the null parameter; typically the null hy-
pothesis assumed it equal to 0. The significance of the interaction term was
further confirmed by the likelihood ratio test on the deviance between the
full model (with interaction term) and the reduced model (without in-
teraction term). Power was assessed through simulation to obtain empirical
distributions for P values. Data were simulated 100 times based on the dis-
tribution of the predictors. The effect (β) of each predictor was used to
determine the outcome (0 or 1). A binary logistic regression was fit on the
simulated dataset, and the P value of the interaction term was extracted.
The power to detect significant interactions with a single copy of SE+V11+
was 0.96, and the power to detect interactions with two copies of SE+V11+
was 0.36. Likewise, the power to detect significant interactions with a
single copy of SE+V11− was 0.82, and the power to detect interactions with
two copies of SE+V11− was 0.70.
The FDR was calculated as described previously (47) and was set to 10%,
giving a significance threshold of P < 0.02 for the primary association analysis.
Correction for multiple testing was performed using the Bonferroni method.
The data supporting the findings of this study are available from the
corresponding author on request.
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